Form 4: Agenus Inc. Director Jennifer Buell Receives Stock in Lieu of Cash Compensation
SEC Form 4 Filing
Agenus Inc. director Jennifer Buell received 776 shares of common stock as part of her compensation in lieu of cash.
Summary
- Jennifer Buell, a director at Agenus Inc., received 776 shares of common stock as part of her compensation.
- This stock was issued in lieu of cash payment for her salary for the pay period ending January 24, 2025.
- The shares were granted under the Amended and Restated Agenus Inc. 2019 Equity Incentive Plan and are fully vested upon issuance.
- The stock was valued at $3.57 per share, which was the closing price of Agenus Inc. common stock on January 24, 2025.
- Following this transaction, Ms. Buell's total holdings decreased by 14,446 shares.
Sentiment
Score: 7
Explanation: The document reflects a standard compensation practice, which is generally viewed neutrally to slightly positive as it aligns director interests with shareholders. There are no negative implications.
Positives
- The use of stock as compensation aligns director interests with shareholder value.
- The shares are fully vested upon issuance, providing immediate ownership to the director.
Management Comments
- A portion of Jennifer Buell's salary is being paid in stock, in lieu of cash, at her request and with the approval of the Agenus Inc. Compensation Committee.
Industry Context
The use of stock-based compensation is a common practice in the biotechnology industry to attract and retain talent, aligning the interests of management with those of shareholders.
Comparison to Industry Standards
- Stock-based compensation is a standard practice across the biotechnology industry, with companies like Regeneron, Gilead, and Amgen also using similar methods to compensate executives and directors.
- The vesting schedule of the shares being fully vested on the date of issuance is common for stock grants in lieu of cash compensation.
Stakeholder Impact
- Shareholders may view this as a positive as it aligns director interests with company performance.
- Employees may see this as a standard practice for executive compensation.
Key Dates
| Date | Description |
|---|---|
| 01/24/2025 | Date of the stock transaction and the end of the pay period for which the stock was issued. |
| 01/28/2025 | Date the Form 4 was signed. |
Keywords
Agenus Inc, Jennifer Buell, stock compensation, equity incentive plan, director compensation, Form 4, insider trading
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.